EUS-guided biopsies versus surgical specimens for establishing patient-derived pancreatic cancer organoids: a systematic review and meta-analysis

Simon Ezban Grützmeier; Hafsa Mahad Mahamud Sodal; Bojan Kovacevic; Peter Vilmann; John Gásdal Karstensen; Pia Klausen

doi:10.1016/j.gie.2024.04.012

EUS-guided biopsies versus surgical specimens for establishing patient-derived pancreatic cancer organoids: a systematic review and meta-analysis

Simon Ezban Grützmeier^*, Hafsa Mahad Mahamud Sodal, Bojan Kovacevic, Peter Vilmann, John Gásdal Karstensen, Pia Klausen

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

2 Citationer (Scopus)

3 Downloads (Pure)

Abstract

Background and Aims: Patient-derived tumor organoids (PDTOs) are a promising new disease model in pancreatic cancer for use in personalized medicine. However, the overall success rate (SR) of establishing these cultures from EUS-guided biopsies is unknown. Methods: We searched relevant database publications reporting SRs of PDTO establishment from pancreatic cancer. The primary outcome was SR stratified on tissue acquisition method (EUS-guided biopsies, percutaneous biopsies, and surgical specimens). Results: Twenty-four studies were identified that included 1053 attempts at establishing PDTOs. Overall SR was 63% (95% confidence interval [CI], 54%-72%). Pooled SRs of PDTO establishment from EUS-guided biopsies, percutaneous biopsies, and surgical specimens were 60% (95% CI, 43%-76%), 36% (95% CI, 14%-61%), and 62% (95% CI, 48%-75%), respectively, and did not differ significantly (P = .1975). Conclusion: The SR of PDTO establishment from EUS-guided biopsies is comparable to that from surgical specimens. Both techniques are suitable for tissue acquisition for PDTOs in clinical and research settings. (PROSPERO registration number: CRD42023425121.)

Originalsprog	Engelsk
Tidsskrift	Gastrointestinal Endoscopy
Vol/bind	100
Udgave nummer	4
Sider (fra-til)	750-755
Antal sider	6
ISSN	0016-5107
DOI	https://doi.org/10.1016/j.gie.2024.04.012
Status	Udgivet - 2024

Bibliografisk note

Funding Information:
The following authors disclosed financial relationships: J.G. Karstensen: consultant for SNIPR BIOME, Boston Scientific, and Ambu. P. Vilmann: consultant for Medi-Globe GmbH. All other authors disclosed no financial relationships. This research was funded by the Danish Cancer Society (grant no. 2021 R322-A17350); the European Research Executive Agency under the project Training in Translational Protocols for Minimal Invasive Diagnosis and Therapy in Pancreatico-Biliary Cancers\u2014TRIP (grant agreement no. 101079210); and Arvid Nilssons Fond, T\u00F8mrermester J\u00F8rgen Holm og hustru, Elisa f. Hansens Mindelegat, Dagmar Marshalls Fond, and L\u00E6geforeningens Forskningsfond.

Publisher Copyright:
© 2024 American Society for Gastrointestinal Endoscopy

Adgang til dokumentet

10.1016/j.gie.2024.04.012Licens: CC BY

FulltextForlagets udgivne version, 865 KBLicens: CC BY

Citationsformater

EUS-guided biopsies versus surgical specimens for establishing patient-derived pancreatic cancer organoids: a systematic review and meta-analysis. / Grützmeier, Simon Ezban; Sodal, Hafsa Mahad Mahamud; Kovacevic, Bojan et al.
I: Gastrointestinal Endoscopy, Bind 100, Nr. 4, 2024, s. 750-755.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{cfa23b84531e433d82509de59f076a37,

title = "EUS-guided biopsies versus surgical specimens for establishing patient-derived pancreatic cancer organoids: a systematic review and meta-analysis",

abstract = "Background and Aims: Patient-derived tumor organoids (PDTOs) are a promising new disease model in pancreatic cancer for use in personalized medicine. However, the overall success rate (SR) of establishing these cultures from EUS-guided biopsies is unknown. Methods: We searched relevant database publications reporting SRs of PDTO establishment from pancreatic cancer. The primary outcome was SR stratified on tissue acquisition method (EUS-guided biopsies, percutaneous biopsies, and surgical specimens). Results: Twenty-four studies were identified that included 1053 attempts at establishing PDTOs. Overall SR was 63% (95% confidence interval [CI], 54%-72%). Pooled SRs of PDTO establishment from EUS-guided biopsies, percutaneous biopsies, and surgical specimens were 60% (95% CI, 43%-76%), 36% (95% CI, 14%-61%), and 62% (95% CI, 48%-75%), respectively, and did not differ significantly (P = .1975). Conclusion: The SR of PDTO establishment from EUS-guided biopsies is comparable to that from surgical specimens. Both techniques are suitable for tissue acquisition for PDTOs in clinical and research settings. (PROSPERO registration number: CRD42023425121.)",

author = "Gr{\"u}tzmeier, {Simon Ezban} and Sodal, {Hafsa Mahad Mahamud} and Bojan Kovacevic and Peter Vilmann and Karstensen, {John G{\'a}sdal} and Pia Klausen",

note = "Publisher Copyright: {\textcopyright} 2024 American Society for Gastrointestinal Endoscopy",

year = "2024",

doi = "10.1016/j.gie.2024.04.012",

language = "English",

volume = "100",

pages = "750--755",

journal = "Gastrointestinal Endoscopy",

issn = "0016-5107",

publisher = "Mosby Inc.",

number = "4",

}

TY - JOUR

T1 - EUS-guided biopsies versus surgical specimens for establishing patient-derived pancreatic cancer organoids

T2 - a systematic review and meta-analysis

AU - Grützmeier, Simon Ezban

AU - Sodal, Hafsa Mahad Mahamud

AU - Kovacevic, Bojan

AU - Vilmann, Peter

AU - Karstensen, John Gásdal

AU - Klausen, Pia

PY - 2024

Y1 - 2024

N2 - Background and Aims: Patient-derived tumor organoids (PDTOs) are a promising new disease model in pancreatic cancer for use in personalized medicine. However, the overall success rate (SR) of establishing these cultures from EUS-guided biopsies is unknown. Methods: We searched relevant database publications reporting SRs of PDTO establishment from pancreatic cancer. The primary outcome was SR stratified on tissue acquisition method (EUS-guided biopsies, percutaneous biopsies, and surgical specimens). Results: Twenty-four studies were identified that included 1053 attempts at establishing PDTOs. Overall SR was 63% (95% confidence interval [CI], 54%-72%). Pooled SRs of PDTO establishment from EUS-guided biopsies, percutaneous biopsies, and surgical specimens were 60% (95% CI, 43%-76%), 36% (95% CI, 14%-61%), and 62% (95% CI, 48%-75%), respectively, and did not differ significantly (P = .1975). Conclusion: The SR of PDTO establishment from EUS-guided biopsies is comparable to that from surgical specimens. Both techniques are suitable for tissue acquisition for PDTOs in clinical and research settings. (PROSPERO registration number: CRD42023425121.)

AB - Background and Aims: Patient-derived tumor organoids (PDTOs) are a promising new disease model in pancreatic cancer for use in personalized medicine. However, the overall success rate (SR) of establishing these cultures from EUS-guided biopsies is unknown. Methods: We searched relevant database publications reporting SRs of PDTO establishment from pancreatic cancer. The primary outcome was SR stratified on tissue acquisition method (EUS-guided biopsies, percutaneous biopsies, and surgical specimens). Results: Twenty-four studies were identified that included 1053 attempts at establishing PDTOs. Overall SR was 63% (95% confidence interval [CI], 54%-72%). Pooled SRs of PDTO establishment from EUS-guided biopsies, percutaneous biopsies, and surgical specimens were 60% (95% CI, 43%-76%), 36% (95% CI, 14%-61%), and 62% (95% CI, 48%-75%), respectively, and did not differ significantly (P = .1975). Conclusion: The SR of PDTO establishment from EUS-guided biopsies is comparable to that from surgical specimens. Both techniques are suitable for tissue acquisition for PDTOs in clinical and research settings. (PROSPERO registration number: CRD42023425121.)

U2 - 10.1016/j.gie.2024.04.012

DO - 10.1016/j.gie.2024.04.012

M3 - Journal article

C2 - 38593932

AN - SCOPUS:85199684618

SN - 0016-5107

VL - 100

SP - 750

EP - 755

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

IS - 4

ER -